Xilio Therapeutics Files Definitive Proxy Statement
Ticker: XLO · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1840233
| Field | Detail |
|---|---|
| Company | Xilio Therapeutics, Inc. (XLO) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Xilio Proxy Statement filed. Annual meeting June 10. Vote your shares!
AI Summary
Xilio Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting on June 10, 2025. The company, incorporated in Delaware with its principal office in Waltham, MA, is in the pharmaceutical preparations industry. This filing outlines the agenda and proposals for the shareholder meeting, which typically includes the election of directors and ratification of auditors.
Why It Matters
This filing provides shareholders with crucial information regarding the company's governance and upcoming decisions, allowing them to make informed voting choices at the annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual shareholder meeting and does not contain new material financial or operational information.
Key Numbers
- 20250610 — Annual Meeting Date (Shareholders will vote on company matters.)
- 20250428 — Filing Date (Date the proxy statement was submitted to the SEC.)
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- April 28, 2025 (date) — Filing Date
- June 10, 2025 (date) — Meeting Date
- Waltham, MA (location) — Company Address
- 2834 (industry_code) — SIC Code for Pharmaceutical Preparations
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Xilio Therapeutics, Inc. to provide shareholders with information for their annual meeting on June 10, 2025, including proposals to be voted upon.
When is the annual shareholder meeting for Xilio Therapeutics, Inc.?
The annual shareholder meeting is scheduled for June 10, 2025.
What is Xilio Therapeutics, Inc.'s primary business?
Xilio Therapeutics, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Where is Xilio Therapeutics, Inc. located?
The company's business and mailing address is 828 Winter Street, Waltham, MA 02451.
What type of filing is this?
This is a Definitive Proxy Statement (DEF 14A) filed under the 1934 Act.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Xilio Therapeutics, Inc. (XLO).